OptimizeRxOPRX +3.84%54 EBITDA Margin % is 7.94% as of Mar. 2026. GuruFocus rates OPRX with a GF Score™ of 54/100 and a GF Value™ of $12.99 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 668 Healthcare Providers & Services companies, OptimizeRx ranks better than 69.31% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. OptimizeRx's EBITDA for the
three
months ended in Mar. 2026 was $1.6 Mil. OptimizeRx's Revenue for the
three
months ended in Mar. 2026 was $19.8 Mil. Therefore, OptimizeRx's EBITDA margin for the quarter that ended in Mar. 2026 was 7.94%.
OptimizeRx (NAS:OPRX) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
OptimizeRx EBITDA Margin % Related Terms
OptimizeRx EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for OptimizeRx's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OPRX vs DH, CCLD, HCAT: EBITDA Margin % Comparison
For the Health Information Services subindustry, OptimizeRx's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OptimizeRx EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, OptimizeRx's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where OptimizeRx's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OptimizeRx (OPRX) has a EBITDA Margin % of 7.94% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on OptimizeRx and its competitors. According to the industry distribution chart, OptimizeRx ranks #205 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 30.7%.
Is OptimizeRx's EBITDA Margin % too high?
OptimizeRx's current EBITDA Margin % is 7.94%. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. OptimizeRx's value of 7.94% is 22.2% below this industry median. Based on the distribution chart, OptimizeRx ranks #205 out of 668 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, OptimizeRx has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does OptimizeRx's EBITDA Margin % compare to DH and CCLD?
According to the Healthcare Providers & Services industry distribution chart, OptimizeRx ranks #205 out of 668 companies for EBITDA Margin %. This puts OptimizeRx in the upper half of its industry. The industry median EBITDA Margin % is 10.21. OptimizeRx's value of 7.94% is 22.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OptimizeRx's current EBITDA Margin % of 7.94% is 22.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on OptimizeRx and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OptimizeRx's current EBITDA Margin % is 7.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OptimizeRx stock overvalued right now?
Based on GuruFocus' analysis, OptimizeRx (OPRX) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.99, compared to a current price of $4.74 — trading 63.5% below its estimated fair value. The current EBITDA Margin % is 7.94% and 22.2% below the Healthcare Providers & Services industry median of 10.21. OptimizeRx's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For OptimizeRx (OPRX), the current EBITDA Margin % is 7.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OptimizeRx (OPRX) Overvalued in 2026?
Based on GuruFocus' analysis, OptimizeRx stock appears to be undervalued.
The current stock price of $4.74 is trading 63.5% below its estimated GF Value™ of $12.99.
GuruFocus considers OptimizeRx to be Significantly Undervalued.
Key valuation signals for OPRX:
EBITDA Margin %: 7.94%
GF Value™: $12.99 vs. price of $4.74 (63.5% below fair value)
Industry Position: 22.2% below the Healthcare Providers & Services median (#205 of 668)
No single metric tells the full story. See the OPRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.
54GF Score
Get the complete analysis for OPRX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OPRX has been successfully added to your 
